← Leaderboards
Richard James Cote
University Of Southern California
$13,022,506
Attributed
$15,344,649
Total exposure
13
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$15,344,649 · 13
By mechanism
R01$9,947,121 · 5
U01$2,630,408 · 1
R33$1,056,199 · 1
RC1$996,077 · 1
R21$714,844 · 2
P01$0 · 2
Top collaborators
- Ashutosh Agarwal5 shared
- Amir Goldkorn2 shared
- Mark Daniel Pegram2 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Akil Merchant$5,893,439
- Amir Goldkorn$4,457,420
- Neil Kaplowitz$21,379,778
- Alicia A. McDonough$8,552,032
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchCancer PatientSamplingBaseCellsHuman SubjectMalignant NeoplasmsEvaluationTechnologyDetectionMalignant Breast NeoplasmNeoplastic ProcessResponseBlood SpecimenBiomarkerBloodSuccessResearch PersonnelNeoplastic CellCostCessation Of LifeNovel StrategiesCollaborationsDevices
Grant awards (42)
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer$524,410
U01 · FY2022 · CA
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer$534,995
U01 · FY2021 · CA
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer$422,658
U01 · FY2020 · CA
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer$560,831
U01 · FY2019 · CA
A comprehensive liquid biopsy platform for detection and prognostication in early stage breast cancer$587,514
U01 · FY2018 · CA
Culturing viably captured circulating tumor cells using conditional reprogramming$199,759
R21 · FY2015 · CA · contact PI
Culturing viably captured circulating tumor cells using conditional reprogramming$181,612
R21 · FY2014 · CA · contact PI
Circulating Tumor Cell Capture & Analysis in a Multi-Center Prostate Cancer Trial$353,750
R01 · FY2013 · CA · contact PI
Circulating Tumor Cell Capture & Analysis in a Multi-Center Prostate Cancer Trial$484,609
R01 · FY2012 · CA · contact PI
Integrated Microdevice to Capture and Detect Circulating Tumor Cells$469,464
R33 · FY2011 · CA · contact PI
Integrated Microdevice to Capture and Detect Circulating Tumor Cells$586,735
R33 · FY2010 · CA · contact PI
Molecular Analysis of NeoAdjuvant Platinum in Triple Negative Breast Cancer$496,078
RC1 · FY2010 · CA
Circulating Tumor Cell Capture & Analysis in a Multi-Center Prostate Cancer Trial$493,402
R01 · FY2010 · CA · contact PI
Multiplexed Nanosensing for DNA and Proteins$620,767
R01 · FY2009 · EB · contact PI
Circulating Tumor Cell Capture & Analysis in a Multi-Center Prostate Cancer Trial$524,400
R01 · FY2009 · CA · contact PI
Molecular Analysis of NeoAdjuvant Platinum in Triple Negative Breast Cancer$499,999
RC1 · FY2009 · CA
Multiplexed Nanosensing for DNA and Proteins$512,260
R01 · FY2008 · EB · contact PI
Multiplexed Nanosensing for DNA and Proteins$93,825
R01 · FY2008 · EB · contact PI
Multiplexed Nanosensing for DNA and Proteins$613,878
R01 · FY2007 · EB · contact PI
Integrated Microdevice to Capture and Detect Circulating Tumor Cells$156,524
R21 · FY2007 · CA · contact PI
MCAV in Organ-Confined Bladder CA based on p53 Status$269,741
R01 · FY2006 · CA · contact PI
Integrated Microdevice to Capture and Detect Circulating Tumor Cells$176,949
R21 · FY2006 · CA · contact PI
MCAV in Organ-Confined Bladder CA based on p53 Status$638,420
R01 · FY2005 · CA
MCAV in Organ-Confined Bladder CA based on p53 Status$548,428
R01 · FY2004 · CA
BONE MARROW &SENTINEL NODE MICROMETASTASES IN BREAST CA$491,893
R01 · FY2004 · CA
MCAV in Organ-Confined Bladder CA based on p53 Status$551,197
R01 · FY2003 · CA
BONE MARROW &SENTINEL NODE MICROMETASTASES IN BREAST CA$478,323
R01 · FY2003 · CA
DETECTION OF OCCULT METASTASES IN LUNG CANCER PATIENTS$329,063
R01 · FY2003 · CA
MVAC IN ORGAN-CONFINED BLADDER CANCER BASED P53 STATUS$503,260
R01 · FY2002 · CA
BONE MARROW &SENTINEL NODE MICROMETASTASES IN BREAST CA$465,150
R01 · FY2002 · CA
DETECTION OF OCCULT METASTASES IN LUNG CANCER PATIENTS$329,063
R01 · FY2002 · CA
Core--Pathology$0
P01 · FY2002 · CA
PILOT--GENITOURINARY CANCER$0
P30 · FY2002 · CA
PILOT--GENITOURINARY CANCER$0
P30 · FY2002 · CA
Molecular /Cellular Pathways of Bladder Cancer Progression$0
P01 · FY2002 · CA
MVAC IN ORGAN-CONFINED BLADDER CANCER BASED P53 STATUS$456,329
R01 · FY2001 · CA
BONE MARROW &SENTINEL NODE MICROMETASTASES IN BREAST CA$455,226
R01 · FY2001 · CA
DETECTION OF OCCULT METASTASES IN LUNG CANCER PATIENTS$139,783
R01 · FY2001 · CA
PILOT--GENITOURINARY CANCER$0
P30 · FY2001 · CA
PILOT--GENITOURINARY CANCER$0
P30 · FY2001 · CA
BONE MARROW &SENTINEL NODE MICROMETASTASES IN BREAST CA$455,712
R01 · FY2000 · CA
DETECTION OF OCCULT METASTASES IN LUNG CANCER PATIENTS$138,642
R01 · FY2000 · CA